Skip to main content
TipRanks
Go Ultimate75% OFF

Exelixis (EXEL) Stock Price & Analysis

3,215 Followers

EXEL Stock Chart & Stats

$69.00-$0.84(-1.20%)
At close: 4:00 PM EST
$50$60$70Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 9
Day’s Range
$68.70 - $69.94
52-Week Range
$39.71 - $73.69
Previous Close
$69.84
Volume
N/A
Average Volume (3M)
2.76M
Market Cap
$16.84B
Enterprise Value
$14.20B
Total Cash (Recent Filing)
$892.02M
Total Debt (Recent Filing)
$162.20M
Price to Earnings (P/E)
20.0
Beta
0.92
Next Earnings
Feb 09, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

CABOMETYX Franchise Leadership And Growth

The core cabozantinib franchise is expanding through both revenue growth and market-share gains across important oncology indications. Leading prescribing positions and rising prescription volume support durable commercial strength, while the established franchise provides a foundation for funding future pipeline development.

Strong Cash Generation And Liquidity

Robust operating and free cash flow, combined with substantial cash and marketable securities, gives Exelixis meaningful financial flexibility. Low leverage further reduces balance-sheet risk and supports continued investment in clinical programs, business development, and shareholder returns without relying heavily on new debt.

Protected Commercial Exclusivity And Pipeline Expansion

The patent ruling extends protection around a key commercial product and helps preserve the economic value of the existing franchise. At the same time, the broad zanzalintinib development program and new candidates create opportunities to diversify growth beyond the current lead medicine over time.

Bears Say

Gross-to-net And Margin Pressure

Higher gross-to-net deductions reduce the revenue retained from reported product sales and can pressure the economics of the commercial franchise. The sharp decline in TTM gross margin also indicates recent cost or mix pressure, which could limit how much revenue growth converts into durable earnings and cash flow.

Delayed Zanzalintinib Regulatory Timeline

The extended FDA review delays a potential zanzalintinib launch in metastatic colorectal cancer and postpones a possible second growth franchise. The delay also reflects the significance of updated safety and efficacy data, keeping regulatory timing and approval execution as material uncertainties for pipeline-driven expansion.

Dependence On The Cabozantinib Franchise

Reliance on one main commercial franchise concentrates Exelixis's revenue base around the continued performance of CABOMETYX and its approved indications. This makes future growth more dependent on sustained prescribing, market access, and successful pipeline launches that can broaden the company's product mix.

Exelixis News

EXEL FAQ

What was Exelixis’s price range in the past 12 months?
Exelixis lowest stock price was $39.71 and its highest was $73.69 in the past 12 months.
What is Exelixis’s market cap?
Exelixis’s market cap is $16.84B.
When is Exelixis’s upcoming earnings report date?
Exelixis’s next earnings report is estimated for Feb 09, 2027 (not yet confirmed), which is in 84 days.
How were Exelixis’s earnings last quarter?
Exelixis released its earnings results on Oct 29, 2026. The company reported $0.94 earnings per share for the quarter, beating the consensus estimate of $0.887 by $0.053.
Is Exelixis overvalued?
According to Wall Street analysts Exelixis’s price is currently Overvalued.
Does Exelixis pay dividends?
Exelixis does not currently pay dividends.
What is Exelixis’s EPS estimate?
Exelixis’s EPS estimate is 1.00.
How many shares outstanding does Exelixis have?
Exelixis has 244,010,900 shares outstanding.
What happened to Exelixis’s price movement after its last earnings report?
Exelixis reported an EPS of $0.94 in its last earnings report, beating expectations of $0.887. Following the earnings report the stock price went up 4.819%.
Which hedge fund is a major shareholder of Exelixis?
Hedge funds hold Exelixis shares: the largest hedge-fund position in Exelixis is 72,325,016 shares, and hedge funds decreased their holdings by 1.3M shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology